LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

LLY

1,023.34

+1.71%↑

JNJ

230.48

+0.46%↑

ABBV

212.01

-0.57%↓

UNH

389.57

-0.81%↓

AZN

187.16

+1.18%↑

Kodu・Aktsiate loetelu・Incyte Corp

Incyte Corp

Avatud

SektorTervishoid

97.34 2.05

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

92.12

Max

97.89

Põhinäitajad
By Trading Economics
Sissetulek	4.1M 303M
Müük	-234M 1.3B
P/E Sektori keskmine	13.445 49.701
Aktsiakasum	1.81
Kasumimarginaal	23.834
Töötajad	2,844
EBITDA	-47M 367M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+14.64% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	28. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-31M 19B
Eelmine avamishind	95.29
Eelmine sulgemishind	97.34

Uudiste sentiment

By Acuity

39%

61%

121 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

59.52 / 62.66 Toetus ja vastupanu

Incyte Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. mai 2026, 20:36 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19. mai 2026, 23:47 UTC

Market Talk

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19. mai 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19. mai 2026, 23:28 UTC

Market Talk

Tulu

Global Forex and Fixed Income Roundup: Market Talk

19. mai 2026, 23:28 UTC

Market Talk

Tulu

F&P Healthcare's Outlook Key for Investors -- Market Talk

19. mai 2026, 23:10 UTC

Market Talk

Global Equities Roundup: Market Talk

19. mai 2026, 23:10 UTC

Market Talk

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19. mai 2026, 22:02 UTC

Tulu

ZTO Express (Cayman): Di Xu to Resign From Board

19. mai 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19. mai 2026, 22:01 UTC

Tulu

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19. mai 2026, 22:00 UTC

Tulu

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19. mai 2026, 21:37 UTC

Tulu

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19. mai 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19. mai 2026, 21:01 UTC

Tulu

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19. mai 2026, 20:58 UTC

Tulu

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19. mai 2026, 20:46 UTC

Kuumad aktsiad

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19. mai 2026, 20:43 UTC

Market Talk

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19. mai 2026, 20:34 UTC

Tulu

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19. mai 2026, 20:32 UTC

Tulu

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19. mai 2026, 20:32 UTC

Tulu

James Hardie Industries 4Q EPS 5c >JHX

19. mai 2026, 20:32 UTC

Tulu

James Hardie Industries 4Q Sales $1.4B >JHX

19. mai 2026, 20:21 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices to Buy Empower Semiconductor for $1.5B

19. mai 2026, 20:18 UTC

Market Talk

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19. mai 2026, 20:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

19. mai 2026, 20:13 UTC

Market Talk

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19. mai 2026, 20:03 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19. mai 2026, 20:03 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19. mai 2026, 20:02 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19. mai 2026, 20:02 UTC

Omandamised, ülevõtmised, äriostud

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19. mai 2026, 19:23 UTC

Market Talk

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Incyte Corp Prognoos

Hinnasiht

By TipRanks

14.64% tõus

12 kuu keskmine prognoos

Keskmine 109.13 USD 14.64%

Kõrge 135 USD

Madal 75 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Incyte Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

17 ratings

Osta

Hoia

Müü

Põhineb 17 analüütiku instrumendi Incyte Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

59.52 / 62.66Toetus ja vastupanu

Bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

121 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation